Endometrial Carcinoma: Diagnosis, Staging, and Treatment
Diagnosis
Obtain endometrial tissue through office-based Pipelle biopsy or dilation and curettage (D&C) to establish histological diagnosis 1. Both methods are acceptable initial approaches, though D&C may provide more representative sampling when Pipelle yields inadequate tissue 1, 2.
Preoperative Workup
- Clinical and gynecological examination to assess uterine size and cervical involvement 1
- Transvaginal ultrasound to evaluate endometrial thickness and myometrial invasion 1, 3
- Pelvic MRI with contrast enhancement is the most accurate imaging modality for assessing myometrial invasion depth and cervical stromal involvement 3, 4
- Complete blood count, liver and renal function profiles 1, 3
- Additional imaging (chest/abdominal CT or FDG-PET-CT) should be considered in high-risk patients (Grade 3, non-endometrioid histology, deep myometrial invasion) to detect extrapelvic disease 1
Staging
Endometrial carcinoma uses the FIGO 2009 surgical staging system 4:
| Stage | Definition |
|---|---|
| IA | No invasion or invasion <50% of myometrium [4] |
| IB | Invasion ≥50% of myometrium [4] |
| II | Cervical stromal invasion [4] |
| IIIA | Serosal/adnexal involvement or positive peritoneal cytology [4] |
| IIIB | Vaginal involvement [4] |
| IIIC | Pelvic or para-aortic lymph node metastasis [4] |
| IVA | Bladder/bowel mucosal invasion [4] |
| IVB | Distant metastases [4] |
Histological Grading (Endometrioid Type)
- Grade 1: ≤5% solid (non-squamous, non-morular) growth 4
- Grade 2: 5–50% solid growth 4
- Grade 3: >50% solid growth 4
- Notable nuclear atypia upgrades the tumor by one grade regardless of architecture 4
Surgical Treatment
Standard surgery consists of total hysterectomy with bilateral salpingo-oophorectomy 1, 3, 5. This is the cornerstone of treatment for all stages.
Surgical Approach
- Minimally invasive surgery (laparoscopic or robotic) is preferred over laparotomy, providing equivalent oncologic outcomes with shorter hospital stays and fewer complications 1, 5
- Robotic approach is particularly beneficial in obese women 1
- Peritoneal washings and thorough abdominal exploration should be performed at the start of surgery 1, 3
Lymph Node Assessment
Lymph node evaluation strategy depends on risk factors 1:
- Omit lymphadenectomy in endometrioid FIGO IA Grade 1-2 disease (lymph node metastasis risk <5%) 1
- Perform lymph node evaluation in non-endometrioid histology, FIGO IB, or Grade 3 disease 1
- Sentinel lymph node biopsy with indocyanine green is emerging as the preferred alternative to systematic lymphadenectomy, with high sensitivity for detecting nodal metastases 1
- Systematic pelvic lymphadenectomy does not improve survival in early-stage disease based on randomized trials 1, 3
Special Considerations
- Omentectomy should be performed for carcinosarcoma and serous-type endometrial cancer 1, 6
- Ovarian preservation may be considered in premenopausal patients with FIGO stage IA Grade 1 endometrioid cancer, but is contraindicated in Lynch syndrome or germline BRCA mutation carriers 1
Risk Stratification and Adjuvant Therapy
Approximately 75% of patients present with Stage I disease, which is subdivided into three risk categories 3, 4:
Low-Risk Disease
Stage IA Grade 1-2 endometrioid histology 3, 4
Intermediate-Risk Disease
Stage IB Grade 1-2 or Stage IA Grade 3 endometrioid histology 3, 4
- Adjuvant pelvic radiotherapy significantly reduces pelvic/vaginal recurrence but does not improve overall survival 3, 4
- Recommend pelvic and/or vaginal brachytherapy in patients ≥60 years with deeply invasive Grade 1-2 or Grade 3 tumors where locoregional relapse risk exceeds 15% 3, 4
High-Risk Disease
Stage IB Grade 3 endometrioid, or any stage with serous, clear-cell, or carcinosarcoma histology 3, 4
- Combined pelvic radiotherapy plus platinum-based chemotherapy (carboplatin/paclitaxel) improves overall survival and progression-free survival compared to radiotherapy alone 3, 4, 6
- Cisplatin and doxorubicin combination significantly improves progression-free survival and overall survival in optimally debulked Stage III-IV disease 3, 6
Advanced and Recurrent Disease
Stage III-IV Disease
- Maximal surgical cytoreduction to no residual macroscopic disease should be attempted in patients with good performance status 6, 7
- Carboplatin/paclitaxel doublet is first-line chemotherapy 6, 7
- Combined chemoradiation reduces risk of relapse or death by 36% 6
Recurrent Disease
- Carboplatin/paclitaxel for platinum-sensitive recurrence 7, 8
- Pembrolizumab plus lenvatinib is FDA-approved for endometrial cancer (all histotypes) after progression on chemotherapy 7
- Single-agent pembrolizumab for MSI-high tumors 7
- Progestational agents (medroxyprogesterone acetate 200 mg daily) are active in steroid-receptor positive Grade 1-2 tumors 3
Fertility-Preserving Options
For highly selected young women with Grade 1 endometrioid adenocarcinoma confined to the endometrium who desire fertility 5:
- Confirm diagnosis with D&C (superior to Pipelle) by specialist gynaecopathologist 5
- Pelvic MRI to exclude myometrial invasion and adnexal involvement 5
- Medroxyprogesterone acetate 400-600 mg/day or megestrol acetate 160-320 mg/day 5
- Durable complete response occurs in ~48% of conservatively treated cases 5
- Close surveillance with repeat endometrial sampling every 3-6 months is mandatory 5
Special Histological Subtypes
Carcinosarcoma
Carcinosarcoma is a high-grade endometrial carcinoma with sarcomatous trans-differentiation 7:
- Complete surgical staging including omentectomy and retroperitoneal lymph node dissection 6
- Combined chemotherapy and radiotherapy for all stages, even early disease 6, 7
- Carboplatin/paclitaxel is first-line chemotherapy 6, 7
Serous and Clear-Cell Carcinoma
Automatically classified as high-risk irrespective of stage or grade 4:
Follow-Up
- History, physical, and gynecological examination every 3-4 months for the first 3 years 5
- Extend to every 6 months during years 4-5 5
- Annual examinations thereafter 5
- Focus on early detection of vaginal or pelvic relapses, which may be amenable to curative treatment 5
Key Pitfalls to Avoid
- Up to 25% of preoperative endometrial sampling diagnoses change after final pathology—do not rely solely on preoperative grade for treatment planning 4
- Frozen-section assessment is unreliable for intraoperative risk stratification—base lymphadenectomy decisions on preoperative risk assessment 4
- Systematic lymphadenectomy does not improve survival in low-risk disease—avoid overtreatment 1
- Pipelle biopsy has limited capacity to identify endometrial polyps—consider D&C if clinical suspicion is high despite negative Pipelle 2